Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

DiaMedica Therapeutics (DMAC) Enterprise Value (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Enterprise Value readings, the most recent being -$51.3 million for Q1 2026.

  • Quarterly Enterprise Value fell 41.33% to -$51.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$51.3 million through Mar 2026, down 41.33% year-over-year, with the annual reading at -$59.9 million for FY2025, 35.66% down from the prior year.
  • Enterprise Value hit -$51.3 million in Q1 2026 for DiaMedica Therapeutics, up from -$59.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$2.8 million in Q3 2022 and bottomed at -$59.9 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$39.8 million, with a median of -$44.1 million recorded in 2024.
  • The largest annual shift saw Enterprise Value skyrocketed 94.22% in 2022 before it tumbled 1571.4% in 2023.
  • DiaMedica Therapeutics' Enterprise Value stood at -$33.5 million in 2022, then tumbled by 57.89% to -$52.9 million in 2023, then increased by 16.54% to -$44.1 million in 2024, then crashed by 35.66% to -$59.9 million in 2025, then grew by 14.29% to -$51.3 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Enterprise Value are -$51.3 million (Q1 2026), -$59.9 million (Q4 2025), and -$55.3 million (Q3 2025).